Disc Medicine

Semaglutide B 3.0 mg/ml PDS290 (internal code NOK0024 / Z2023097) is an approved obesity therapeutic sponsored by Disc Medicine. The program is based on semaglutide, a GLP-1 receptor agonist marketed as OZEMPIC by Novo Nordisk. The drug is formulated as a solution for subcutaneous administration and is classified within the alimentary tract and metabolism therapeutic class (A10). Semaglutide has achieved regulatory approval across multiple major markets including Australia, the European Union, Japan, and the United States, with first Australian listing dating to July 2020. The latest disclosed milestone indicates investigation of semaglutide 2.4 mg dosing in low responders following bariatric surgery, reflecting a label expansion strategy targeting patients with inadequate weight loss outcomes post-surgical intervention. The program remains in active status with approved regulatory standing, positioning it within an established competitive landscape of diabetes and obesity therapeutics.

Obesity represents a significant unmet medical need with limited pharmacological options demonstrating sustained efficacy in weight management, particularly in patients with suboptimal response to surgical intervention. The bariatric surgery low-responder population constitutes a clinically relevant subset with few evidence-based treatment alternatives, creating a distinct market opportunity. Semaglutide's established safety and efficacy profile, combined with its GLP-1 mechanism, positions it as a potential solution for post-bariatric patients experiencing weight regain or inadequate initial weight loss. The competitive landscape includes multiple diabetes and weight management agents (SAXENDA, FORXIGA, INVOKANA, ONGLYZA, TRAJENTA, NESINA, VIPIDIA, ACTOS, ZYNQUISTA, QTRILMET, TRAZEC, REPAGLINIDE SUN), yet few specifically address the bariatric low-responder indication. Commercial significance derives from the growing bariatric surgery population and the substantial healthcare burden of obesity-related comorbidities. Disc Medicine's sponsorship suggests a focused development strategy targeting this underserved patient population, potentially enabling differentiated market positioning and premium pricing relative to first-line obesity agents.

Drug Class: GLP-1 receptor agonist

Modality: Small molecule

Route of Administration: Subcutaneous solution injection

Formulation: 3.0 mg/ml concentration

Brand Name: OZEMPIC (Novo Nordisk)

Active Ingredient: Semaglutide

Therapeutic Classification: Alimentary tract and metabolism (A10)

Mechanism of Action: Not yet disclosed in available documentation

Molecular Target: Not yet disclosed in available documentation

Related Therapies: Other GLP-1 agonists and weight management agents including SAXENDA (liraglutide), FORXIGA (dapagliflozin), INVOKANA (canagliflozin)

First Approval: Semaglutide achieved initial regulatory approval in Australia on 1 July 2020; subsequent approvals in EU, Japan, and US markets followed

Patent Status: Not yet disclosed

Australia (TGA): Semaglutide approved with multiple PBS codes (12075M, 12080T, 14149M, 14163K, 14844G, 14846J, 15311W, 15322K) and sponsor Novo Nordisk Pharmaceuticals Pty. Limited. First listing 1 July 2020; additional listings 1 June 2024 and 1 June 2025.

European Union (EMA): Semaglutide approved under marketing authorisation holder Novo Nordisk A/S with four EMA product numbers (EMEA/H/C/004174, EMEA/H/C/004953, EMEA/H/C/005422, EMEA/H/C/006426). Authorisation dates 26 March 2026 and 30 March 2026.

Japan (PMDA): Semaglutide approved in March 2023.

United States (FDA): Semaglutide approved with multiple NDA applications (NDA209637, NDA213051, NDA213182, NDA215256, NDA218316) and ANDA220314. Sponsors include Novo Nordisk Inc and Apotex Inc.

China (NMPA): Clinical trials ongoing; NCT05877547 indicates active investigational status.

Expected Loss of Exclusivity: Not yet disclosed.

Strategic Positioning: Disc Medicine's sponsorship of this program suggests a focused development strategy targeting the bariatric low-responder population, a clinically defined subset with limited pharmacological alternatives. This represents a label expansion opportunity rather than de novo development, leveraging semaglutide's established safety and efficacy profile.

Competitive Implications: The bariatric low-responder indication addresses a gap in the competitive landscape where few agents demonstrate efficacy. This positioning differentiates the program from first-line obesity therapeutics and may support premium pricing and market exclusivity through clinical differentiation rather than patent protection.

Regulatory Pathway: Existing approvals across Australia, EU, Japan, and US provide regulatory precedent and facilitate expedited pathways for indication expansion. The ongoing China trial (NCT05877547) indicates geographic expansion strategy in emerging markets.

Future Catalysts: Expected milestones include completion of bariatric low-responder trial data, regulatory submissions for indication expansion in major markets, and potential label updates reflecting this patient population. Commercial launch timing in the bariatric indication will depend on trial completion and regulatory approval timelines.

Market Opportunity: The global bariatric surgery population exceeds 1 million annual procedures, with 15-30% experiencing suboptimal weight loss outcomes. This represents a substantial addressable population with high unmet medical need and potential for sustained revenue generation.